Subcutaneous pembrolizumab is a viable treatment option for mNSCLC

Addition of radical prostatectomy to systemic treatment improves survival in oligometastatic prostate cancer

NeuroSAFE-guided RARP improves surgical precision for patients with localised prostate cancer

The added value of integrative medicine

Urine test could reduce post-op scans for kidney cancer by half

Micro-ultrasound is as effective as MRI in detecting prostate cancer

Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC

Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer

Adjuvant docetaxel shows no significant advantage compared to surveillance in high-risk prostate cancer after 10 years

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy

EAU 2025: Updates in NMIBC

Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer